ArticleVaccine2025
Emergence of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under five years of age in the 13-valent pneumococcal conjugate vaccine era in Tanzania. A short communication.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ZPY-CpG-Ch, a broad coverage vaccine againstScience advances · 2026Article
Corrections and comments
- Republished from
Authors and funding
7 authors.
Funding
Abstract
To determine the impact of pneumococcal vaccination on nasopharyngeal carriage in Tanzania, we assessed the serotype distribution of S. pneumoniae isolated from nasopharyngeal swab samples. These samples were collected in 539 children below the age of 5 years in two cross-sectional studies, one before and one after PCV13 rollout. In the second study, post-PCV13 rollout, only children who completed the PCV13 vaccination schedule, were included. From the study conducted before the introduction of PCV13, 61 (55 %) of S. pneumoniae serotypes were vaccine types, compared to 89 (23.3 %) post-PCV13. The most common serotypes in the pre-PCV13 period were 19F (n = 23, 20.7 %) and 6B (n = 11, 9.9 %). In the post-PCV13 era, serotypes 15B/C (n = 40, 10.5 %), and 3 (n = 29, 7.6 %) were most prevalent. We observed the emergence of 14 non-vaccine serotypes not detected in the pre-vaccine era. Further surveillance is needed to assess shifts in carriage and their implications for the protection against invasive pneumococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.